Key takeaways
- Three houses dominate injectables—Allergan (Botox, Juvéderm, Allē), Galderma (Dysport, Restylane, Sculptra, ASPIRE), and Merz (Xeomin, Xperience+)—with Revance, Evolus, Prollenium, Suneva, and Croma pressing on price and innovation.
- Loyalty programs are patient-retention rails, not fluff: Allē's ~6 million members route consumers back to participating practices, so choosing a primary toxin means choosing a loyalty ecosystem.
- Medical-grade skincare runs on retail economics—roughly keystone margin—so favor channel-protected lines like skinbetter science and Alastin that block online discounters.
- Buy compliantly or not at all: licensed prescriber, authorized channels only, and never grey-market importers—the FDA issued 18 warning letters in November 2025 over unapproved botulinum toxin.
- Injectable pricing is rep-negotiated: volume tiers, portfolio bundling, rebates, and co-op marketing dollars all move your effective cost.
- Most successful med spas carry two toxin accounts and two to three filler families—enough choice for patients, enough concentration to hit volume tiers.
Injectables and professional skincare are the inventory of a med spa the way software never is: every vial of toxin and every syringe of filler you buy is cost of goods sold, and the supplier relationships behind them decide your margins, your loyalty economics, and even which patients walk through the door asking for you by name. Choosing your injectable and product suppliers is therefore a genuine strategic decision—one that shapes pricing power, retention, and compliance risk for years. This guide walks through the major manufacturers, the loyalty programs that have become the real battleground, medical-grade skincare economics, and the compliance rules you cannot afford to get wrong. Browse every supplier we cover in our injectables and products category.
The injectable houses
The neurotoxin and filler market is dominated by three full-portfolio houses, with a set of credible challengers pressing on price and innovation.
The big three:
- Allergan Aesthetics (an AbbVie company) owns Botox—the brand patients ask for by name—plus the Juvéderm filler family, Kybella, SkinMedica skincare, and the Allē loyalty program. It is the reference account for most American med spas.
- Galderma fields the widest portfolio spread: Dysport toxin, the Restylane filler line, Sculptra (the leading biostimulator), and the ASPIRE Galderma Rewards program, plus Alastin skincare after its acquisition. It is the world's largest independent dermatology company and went public in 2024.
- Merz Aesthetics brings Xeomin (a "naked" toxin with no complexing proteins), Radiesse, Belotero, and Ultherapy, tied together by the Xperience+ loyalty program.
The challengers:
- Revance sells Daxxify, the long-duration peptide-formulated toxin, alongside the RHA resilient hyaluronic-acid filler collection.
- Evolus built Jeuveau as a pure-play aesthetic toxin with aggressive pricing and the digital-first Evolus Rewards program, now expanding into the Evolysse filler line.
- Prollenium offers the Revanesse filler family, often at sharper wholesale pricing than the majors.
- Suneva Medical markets Bellafill, the long-lasting collagen-PMMA filler for patients seeking multi-year duration.
- Croma-Pharma is the European hyaluronic-acid specialist behind the Saypha line, expanding its U.S. footprint.
Most established practices anchor on one or two houses and add challengers opportunistically—for a price advantage, a duration story, or a specific indication the majors don't cover.
Loyalty programs are the battleground
If you take one idea from this guide, take this: manufacturer loyalty programs are not marketing fluff—they are patient-retention rails that route consumers back to practices carrying that brand. Allergan's Allē is the giant, with roughly 6 million members, and it functions as a consumer network: patients earn points on Botox and Juvéderm treatments, receive brand promotions, and are nudged to rebook at Allē-participating practices. Galderma's ASPIRE Rewards plays the same game across Dysport, Restylane, and Sculptra, and Evolus Rewards counters with a simpler digital experience and aggressive consumer offers. Merz's Xperience+ rounds out the majors.
When you choose a primary toxin, you are really choosing which loyalty ecosystem your patients will live in. A practice whose patient base is already full of Allē members faces real switching friction; conversely, a challenger brand's richer promotions can subsidize your acquisition offers, and program gift-card campaigns can fill slow weeks on the manufacturer's dime. Ask each rep how program points, practice-level rebates, and consumer promotions stack—and who owns the patient communication, because the manufacturer emailing your patients directly is both a retention asset and a dependency you should walk into with open eyes.
Medical-grade skincare & retail
Professional skincare is the second half of the portfolio decision, and it runs on classic retail economics rather than per-unit injectable math. Lines like SkinCeuticals, ZO Skin Health, Obagi Medical, skinbetter science, Alastin, and EltaMD anchor the medical-grade tier, with Revision Skincare, iS Clinical, PCA Skin, Colorescience, Jan Marini, and Epionce filling out serious retail shelves.
Two distinctions matter. First, back-bar versus retail: back-bar sizes are consumables you use in treatments, while retail units generate roughly keystone (about 50%) margin at the front desk. Second, channel protection: lines like skinbetter science and Alastin restrict online discounting and unauthorized resellers, which protects your margin from Amazon undercutting; loosely controlled lines can leave you stocking product your patients buy cheaper online. Favor channel-protected lines for the shelf, and pair skincare to your treatment mix—pre/post-procedure protocols attach naturally to injectable and device visits.
Buying compliantly
This section is non-negotiable. Injectables are prescription medical products: they must be ordered by or under a licensed prescriber appropriate to your state (physician, or NP/PA where permitted), and they must come only through authorized channels—the manufacturer or its designated distributors. The FDA has repeatedly cracked down on counterfeit and unapproved Botox moving through grey-market suppliers, including a wave of 18 warning letters in November 2025 to distributors selling unapproved botulinum toxin products. Counterfeit toxin has hospitalized patients, and buying it exposes your license, your insurance, and your patients.
Never buy from grey-market importers, "discount pharma" emailers, or any seller offering pricing dramatically below your rep's quote. Verify your account is registered directly with Allergan, Galderma, Merz, Revance, Evolus, or their authorized distributors, keep purchase records, and confirm cold-chain handling on receipt.
Account mechanics
Injectable pricing is rep-negotiated, not posted. Expect list-price anchors, then volume tiers, quarterly commitments, and bundled discounts across a manufacturer's portfolio (toxin plus filler plus skincare). The mechanics to negotiate:
- Volume tiers: unit and syringe pricing steps down at committed quarterly volume—know your real run rate before committing.
- Portfolio bundling: carrying a house's filler and skincare usually improves your toxin price.
- Rebates and points: practice-level rebates through Allē, ASPIRE, and Evolus Rewards meaningfully lower effective cost—model them in.
- Co-op marketing: the majors fund open houses, consumer offers, and social campaigns for good accounts; ask what marketing dollars come with each tier.
- Payment terms and samples: net terms, evaluation stock, and training support are all negotiable.
Treat the rep relationship as an ongoing negotiation, not a one-time signup: volumes change, competitors call, and the houses re-price accounts far more often than their list sheets suggest. Re-quote your anchor account at least annually.
Matching portfolio to your patient base
There is no single right stack—there is a right stack for your patients. A practice serving brand-driven consumers who ask for Botox by name needs Allergan as its anchor. A practice competing on value can lead with Evolus or Prollenium pricing. A regenerative, natural-results positioning argues for Galderma's Sculptra and Restylane depth, while longevity-focused patients may justify Revance's Daxxify or Suneva's Bellafill. Match your skincare shelf the same way: acne and pigment programs (ZO, Obagi, PCA) versus antioxidant prestige (SkinCeuticals, iS Clinical) versus procedure-recovery (Alastin) versus daily photoprotection (EltaMD, Colorescience).
Most successful med spas carry two toxin accounts and two to three filler families—enough choice to serve patients and enough concentration to hit volume tiers.
Ready to go deeper? Explore every supplier in the injectables and products category, see what wholesale and retail really cost in our injectables pricing guide, read the head-to-head Allergan vs Galderma comparison, and review our methodology to see how we evaluate suppliers.
Frequently asked questions
Which injectable brands should a new med spa carry first?
Most new practices anchor on one of the big three—Allergan (Botox and Juvéderm), Galderma (Dysport, Restylane, Sculptra), or Merz (Xeomin)—because patients recognize the brands and the loyalty programs drive rebooking. Botox remains the name patients ask for, so many practices open an Allergan account first, then add a second toxin (Dysport, Jeuveau, or Xeomin) for choice and pricing leverage. Add challenger brands like Revance's Daxxify or Prollenium's Revanesse once you know your patient base and volumes.
How important are loyalty programs like Allē and ASPIRE?
Very. Allē (Allergan) counts roughly 6 million consumer members, and ASPIRE (Galderma) and Evolus Rewards play the same role for their portfolios. These programs award patients points for treatments, push brand promotions, and route members back to participating practices—so they function as retention infrastructure. When you pick a primary toxin, you're effectively picking the loyalty ecosystem your patients will live in, and switching later means fighting accumulated points and habits.
Can I buy Botox or fillers from discount online suppliers?
No. Injectables are prescription medical products that must be ordered under a licensed prescriber and purchased only through the manufacturer or its authorized distributors. Grey-market importers and 'discount pharma' sellers are how counterfeit and unapproved toxin enters the market—the FDA sent 18 warning letters in November 2025 to distributors selling unapproved botulinum toxin, and counterfeit product has hospitalized patients. Pricing far below your rep's quote is a red flag, not a deal.
What margin should I expect on medical-grade skincare?
Retail skincare typically runs near keystone pricing—roughly a 50% margin on the shelf price—while back-bar sizes are treatment consumables rather than profit lines. The margin only holds if the line is channel-protected: brands like skinbetter science and Alastin restrict unauthorized online resellers so patients can't undercut you on Amazon. Loosely controlled lines can leave you stocking product that sells cheaper online, so ask every skincare rep about their reseller enforcement before committing shelf space.
How do I negotiate better injectable pricing?
Injectable pricing is rep-negotiated, so come prepared with your real quarterly volumes. Ask about volume tiers (pricing steps down at committed volume), portfolio bundling (carrying a house's filler and skincare usually improves your toxin price), practice-level rebates through the loyalty programs, and co-op marketing funds for events and promotions. Carrying a credible second toxin account gives you leverage in every conversation, and payment terms, samples, and training support are all negotiable too.
